Par Drugs And Chemicals Limited (NSE: PAR) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹145 Cr, it ranks #2,919 by market cap among the 6,197 Indian listed companies on FinBizNet, and #60 of 86 in Medicinal Chemicals and Botanical Products. At ₹119.00 (as of 16 Nov 2026), the share price is 33.9% below its 52-week high of ₹180.00 and 52.5% above its 52-week low of ₹78.05. The share price is up 20.0% over one year and up 19.7% over three months.
| Current Price | ₹119.00 |
|---|---|
| Market Cap | ₹145 Cr |
| NSE Symbol | PAR |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 10.9 |
| Return on Equity | 12.43% |
| Return on Assets | 6.75% |
| 52-Week Range | ₹78.05 – ₹180.00 |
| 1-Year Price Change | +20.0% |
| 3-Month Price Change | +19.7% |
| Beta (1Y) | 0.55 |
| Dividend Yield | 0.00% |
| Headquarters | Vadodara, Gujarat |
| Website | www.pardrugs.com |
| Revenue | ₹27 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 9.6% |
| EPS (Basic) | ₹2.14 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Par Drugs And Chemicals Limited reported revenue of ₹27 Cr in Q2 FY27, down 4.3% from ₹29 Cr in Q2 FY26 and down 12.3% from ₹31 Cr in Q1 FY27. It posted a net profit of ₹3 Cr for the quarter, against a net profit of ₹4 Cr in Q2 FY26 (down 36.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹20 Cr (Q4 FY26) to ₹31 Cr (Q1 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹27 Cr | ₹3 Cr | 9.6% |
| Q1 FY27 | ₹31 Cr | ₹5 Cr | 15.1% |
| Q4 FY26 | ₹20 Cr | ₹1 Cr | 4.3% |
| Q3 FY26 | ₹29 Cr | ₹5 Cr | 16.4% |
| Q2 FY26 | ₹29 Cr | ₹4 Cr | 14.4% |
| Q1 FY26 | ₹26 Cr | ₹3 Cr | 12.8% |
| Q4 FY25 | ₹22 Cr | ₹2 Cr | 7.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 73.41% of Par Drugs And Chemicals Limited's shares as of Sept 2026, against 73.37% in Sept 2025 (+0.04 percentage points).
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
1. Manufacturing of API-This segment manufactures and sells active pharmaceutical ingredients.
1. Manufacturing of API-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Par Drugs And Chemicals Limited | ₹145 Cr | 10.9 | 12.43% | ₹27 Cr | +20.0% |
Listed by market capitalisation. Ratios are shown for context only.
Par Drugs And Chemicals Limited is trading at ₹119.00, with a market capitalisation of ₹145 Cr.
Par Drugs And Chemicals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Par Drugs And Chemicals Limited has a P/E of 10.9 and a return on equity of 12.43%.
Par Drugs And Chemicals Limited is listed on the NSE under the symbol PAR.
Par Drugs And Chemicals Limited's share price is up 20.0% over one year and up 19.7% over three months. Its 52-week range is ₹78.05 to ₹180.00.
In Q2 FY27, Par Drugs And Chemicals Limited reported revenue of ₹27 Cr and net profit of ₹3 Cr, with basic EPS of ₹2.14 (standalone, parsed from the company's exchange filing).
Par Drugs And Chemicals Limited reported revenue of ₹27 Cr in Q2 FY27, down 4.3% from ₹29 Cr in Q2 FY26 and down 12.3% from ₹31 Cr in Q1 FY27.
Promoters held 73.41% of Par Drugs And Chemicals Limited's shares as of Sept 2026, against 73.37% in Sept 2025 (+0.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.